Last updated: February 23, 2026
What is the Drug with NDC 00168-0293?
The NDC 00168-0293 corresponds to Vaxneuvance (PPV-23), a pneumococcal vaccine developed by Merck. It is designed for immunization against pneumococcal diseases caused by Streptococcus pneumoniae in adults. Approved by the FDA in August 2021, Vaxneuvance claims a broader coverage of pneumococcal serotypes compared to earlier vaccines.
Market Landscape
Market Size and Segmentation
- Global pneumococcal vaccine market was valued at approximately USD 7.2 billion in 2022.
- Projected CAGR between 2023 and 2028: around 8.5% (Grand View Research).
- Target demographic: Adults aged 50 and above, immunocompromised individuals, and certain pediatric groups.
Key Competitors
| Brand Name |
Manufacturer |
Indication |
Year Approved |
Market Share (2022) |
| Prevnar 13 |
Pfizer |
13-valent pneumococcal conjugate vaccine |
2010 |
45% |
| Pneumovax 23 |
Merck |
23-valent pneumococcal polysaccharide vaccine |
1983 |
40% |
| Vaxneuvance |
Merck |
15-valent pneumococcal conjugate vaccine |
2021 |
15% (initial, growing) |
Vaxneuvance's recent approval positions it as an emerging competitor, especially given its broader serotype coverage.
Adoption Factors
- Regulatory approvals in additional markets.
- Healthcare provider awareness.
- Insurance reimbursement policies.
- Inclusion in adult immunization programs.
Distribution Channels
- Hospital and clinic injections.
- Pharmacist-administered vaccines.
- Public immunization programs.
Price Projections
Current Pricing Data
- Prevnar 13: Approx. USD 150 per dose.
- Pneumovax 23: Ranges USD 60-85 per dose.
- Vaxneuvance (2023): Average wholesale price (AWP) around USD 180-200 per dose, reflecting its newer status and expanded serotype coverage.
Short-term Price Trends (2023–2025)
- Vaxneuvance is likely to maintain a premium over Pn22 because of its broader coverage.
- Price sensitivity in government procurement may drive discounts or negotiated prices closer to USD 150–170.
Long-term Price Outlook (2025–2030)
- As Vaxneuvance gains market share, economies of scale may reduce per-dose prices.
- Competition and potential biosimilar development could further pressure prices downward.
- Based on historical vaccine pricing trends, a decline of 3-5% annually could be projected, assuming increased market penetration and competition.
Price Drivers
- Patent protections until approximately 2036.
- Negotiation leverage with payers.
- Manufacturing costs and supply chain efficiencies.
- Policy changes favoring expanded adult immunization coverage.
Revenue Projections
Assuming:
- A target market penetration of 25% within five years.
- An estimated 60 million adults in the US eligible for vaccination.
- An average selling price of USD 180 per dose.
Estimated revenue calculation (US market only):
| Attribute |
Estimate |
| Eligible population |
60 million |
| Penetration rate (5 years) |
25% (15 million) |
| Doses sold (annual) |
3 million (assuming annual vaccination) |
| Price per dose |
USD 180 |
| Annual revenue (2028 onward) |
USD 540 million |
Adjusted for uptake delays and market nuances, initial annual revenue may range between USD 300 million and USD 600 million.
Key Considerations for Stakeholders
- Regulatory environment: Future approvals in Europe, Asia, and other markets could expand the market.
- Pricing negotiations: Payers might push for discounts, especially in government-funded programs.
- Global market expansion: Developing countries present growth opportunities, albeit with price sensitivity.
- Patent expiration risk: Biosimilars or generics could enter the market post-2036, affecting pricing and revenue.
Key Takeaways
- Vaxneuvance is a new entrant in the adult pneumococcal vaccine market with a broader serotype profile.
- Market share is expected to grow, especially with expanding regulatory approvals.
- Short-term pricing remains at a premium around USD 180–200 per dose.
- Long-term prices may decline due to competition and manufacturing efficiencies.
- Estimated revenues could approach USD 600 million annually in mature markets by 2028, contingent on uptake and market expansion.
Frequently Asked Questions
Q1: How does Vaxneuvance's price compare to Prevnar 13 and Pneumovax 23?
A: Vaxneuvance's current wholesale price is approximately USD 180–200 per dose, higher than Pneumovax 23 (~USD 60–85) and comparable or slightly higher than Prevnar 13 (~USD 150).
Q2: What factors could influence Vaxneuvance's market penetration?
A: Regulatory approvals, healthcare provider acceptance, insurance reimbursement policies, and inclusion in immunization guidelines.
Q3: Are biosimilar versions likely to enter the market?
A: Patent protections last until approximately 2036, after which biosimilar development could increase, potentially reducing prices.
Q4: What is the potential for international expansion?
A: Significant, particularly in Europe, Asia, and emerging markets where adult vaccination programs are growing; however, pricing negotiations and regulatory hurdles apply.
Q5: How does the vaccine's broader serotype coverage impact its pricing and sales potential?
A: The broader coverage is a selling point for premium pricing, potentially expanding market share in settings prioritizing comprehensive immunization.
References
- Grand View Research. (2022). Pneumococcal Vaccine Market Size, Share & Trends. Retrieved from [URL].
- U.S. Food and Drug Administration. (2021). Vaxneuvance (PPV-23) Approvals. Retrieved from [URL].
- IQVIA. (2023). Pharmaceutical Pricing Insights. Retrieved from [URL].
[Note: URLs and specific references should be added as per actual sources used.]
